Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review.
ART
Cobicistat
HIV
SOT
Transplant recipient
Transplantation
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
28
01
2021
accepted:
02
03
2021
pubmed:
9
4
2021
medline:
9
4
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
People living with HIV should be considered candidates for solid-organ transplantation (SOT). However, managing HIV-infected patients undergoing SOT represents a major challenge due to the potential drug-drug interactions between antiretroviral drugs and immunosuppressive agents, particularly when resorting to antiretroviral drugs that require pharmacokinetic enhancers. We report three cases of cobicistat-tacrolimus co-administration, two of which also include the co-administration of mTOR inhibitors, in HIV-positive patients undergoing SOT (2 kidney and 1 liver recipient). We review previously reported cases and provide recommendations for initial management following transplantation.
Identifiants
pubmed: 33830489
doi: 10.1007/s40121-021-00430-w
pii: 10.1007/s40121-021-00430-w
pmc: PMC8027707
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1055-1064Subventions
Organisme : REDINREN
ID : RD16/0009/0013
Références
Van Maarseveen EM, Rogers CC, Trofe-Clark J, Van Zuilen AD, Mudrikova T. Drug–drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS. 2012;26:568–81.
doi: 10.1089/apc.2012.0169
Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults. Expert OpinPharmacother. 2018;19:49–64.
doi: 10.1080/14656566.2017.1419185
Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25.
doi: 10.1056/NEJMoa1503153
Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–13.
doi: 10.1056/NEJMoa1501315
Farahani M, Mulinder H, Farahani A, Marlink R. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. Int J STD AIDS. 2017;28:636–50.
doi: 10.1177/0956462416632428
Shah BM, Schafer JJ, Priano J, Squires KE. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013;33:1107–16.
doi: 10.1002/phar.1237
Barbarino JM, Staatz CE, Venkataramanan R, et al. PharmGKB summary: cyclosporine and tacrolimus pathways. PharmacogenetGenom. 2013;23:563–85.
Curran A, Pérez-Valero I, Moltó J. Rezolsta
pubmed: 26035169
Salgo R, Gossman J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385–93.
doi: 10.1111/j.1600-6143.2009.02997.x
Kearney L, Hogan D, Conlon P, Roche M, O’Neill JP, Sullivan JB. High-risk cutaneous malignancies and immunosuppression: challenges for the reconstructive surgeon in the renal transplant population. J PlastReconstrAesthetSurg. 2017;70:922–30.
Nguyen LS, Vautier M, Allenbach Y, et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf. 2019;42:813–25.
doi: 10.1007/s40264-018-0758-8
Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of gs-9350: a novel pharmacokinetic enhancer without anti-HIV activity. ClinPharmacolTher. 2010;87:322–9.
Sherman EM, Worley MV, Unger NR, Gauthier TP, Schafer JJ. Cobicistat: review of a pharmacokinetic enhancer for HIV infection. ClinTher. 2015;37:1876–93.
Van Maarseveen EM, Crommelin HA, Mudrikova T, van den Broek MPH, van Zuilen AD. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. Transplantation. 2013;95:397–402.
doi: 10.1097/TP.0b013e3182734651
Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipients. FundamClinPharmacol. 2009;23:423–5.
Bickel M, Anadol E, Vogel M, et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J AntimicrobChemother. 2010;65:999–1004.
Mertz D, Battegay M, Marzolini C, Mayr M. Drug–drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis. 2009;54:e1–4.
doi: 10.1053/j.ajkd.2009.01.268
Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother. 2003;37:1793–6.
doi: 10.1345/aph.1D076
Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transplant. 2003;9:954–60.
doi: 10.1053/jlts.2003.50171
Han Z, Kane BM, Petty LA, Josephson MA, Sutor J, Pursell KJ. Cobicistat significantly increases tacrolimus serum concentrations in a renal transplant recipient with human immunodeficiency virus infection. Pharmacotherapy. 2016;36:e50–3.
doi: 10.1002/phar.1752
Patel SJ, Kuten SA, Musick WL, Gaber AO, Monsour HP, Knight RJ. Combination drug products for HIV—a word of caution for the transplant clinician. Am J Transplant. 2016;16:2479–82.
doi: 10.1111/ajt.13826
Bartiromo M, Borchi B, Botta A, et al. Threatening drug–drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). Transpl Infect Dis. 2020;22:1–4.
doi: 10.1111/tid.13286
De Meyer S, Bojkova D, Cinatl J, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. Int J Infect Dis. 2020;97:7–10.
doi: 10.1016/j.ijid.2020.05.085
Blumberg EA, Rogers CC. Solid organ transplantation in the HIV-infected patient: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:1–15.
doi: 10.1111/ctr.13499
Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011;79:825–42.
doi: 10.1038/ki.2010.545
Locke JE, Mehta S, Reed R, et al. A national study of outcomes among HIV-infected kidney transplant recipients. J Am SocNephrol. 2015;26:2222–9.
Zheng X, Gong L, Xue W, et al. Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis. BioMed Central. 2019;16:37.
Grottenthaler JM, Werner CR, Steurer M, et al. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. PLoS ONE. 2018;13:1–12.
doi: 10.1371/journal.pone.0197544
Manzardo C, Lodoño MC, Castells L, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: a prospective nationwide cohort study. Am J Transplant. 2018;18:2513–22.
doi: 10.1111/ajt.14996
Hemmersbach-Miller M, Berg CL, Messina JA, Wolfe CR. Transplant drug interactions and a word of caution for the HIV provider. A case report. Open Forum Infect Dis. 2018;5:4–5.
doi: 10.1093/ofid/ofy070